|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The method was applied to the assay of p53 in human plasma sample and normal and malignant cell line lysates such as normal cell Line from mouse C3H (L929), colon cancer cell-HCT, prostate cancer cell line PC-3, and human breast adenocarcinoma cell line-MCF7.
|
29113888 |
2018 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, SOCS2 was upregulated by p53 dysfunction and seemed to be associated with the tumorigenic potential of colon cancer.
|
29622769 |
2018 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Wild-type p53 expressing HCT116 colon cancer cells were resistant to apoptosis in response to the MDM2 antagonist Nutlin-3a.
|
29394130 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is highly desirable to activation p53 function with small-molecule compounds for colon cancer therapy.
|
30142612 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To gain a more in-depth understanding of metabolic regulation by baseline levels of p53, we employed both metabolomics and transcriptomics analysis with human colon cancer cell-line HCT116 depleted of p53.
|
29323703 |
2018 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The assessment of both CUL4A and mutant TP53 expression will be helpful in predicting colon cancer prognosis.
|
30562757 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, miR-423-5p induced the expression of caspases 3, 8 and 9, as well as p53 in colon cancer.
|
30116373 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRRAP silencing attenuated p53 accumulation in lymphoma and colon cancer models, whereas TRRAP overexpression increased mutp53 levels, suggesting a role for TRRAP across cancer entities and p53 mutations.
|
29653964 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings present the first to elucidate that miR-29c is a direct p53 target gene, and also identify PHLDB2 as an important miR-29c target gene involved in colon cancer metastasis.
|
28392396 |
2017 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, the method was applied to the assay of p53 in human plasma sample and normal and malignant cell line lysates such as (L929 normal cell Line from mouse C3H (L929), colon cancer cell-HCT, prostate cancer cell line PC-3, and human breast adenocarcinoma cell line-MCF7).
|
28774804 |
2017 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we report a new electrochemical method for early detection of p53 autoantibodies against colon cancer using a strategy that combines the strength of gold-loaded nanoporous iron oxide nanocube (Au@NPFe<sub>2</sub>O<sub>3</sub>NC)-based capture and purification while incorporating the inherent simplicity, inexpensive, and portable nature of the electrochemical and naked-eye colorimetric readouts.
|
28627551 |
2017 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Wild-type and mutant p53 differentially modulate miR-124/iASPP feedback following pohotodynamic therapy in human colon cancer cell line.
|
29022915 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAK4 regulates G6PD activity by p53 degradation involving colon cancer cell growth.
|
28542136 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the present study revealed that the loss of p53 expression levels in tumors was associated with aggressive clinicopathological characteristics in patients with colon cancer.
|
28521456 |
2017 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this population-based cohort study, the interaction between p53 and 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR) expression, KRAS mutations, and the association between statin use and colon cancer survival was assessed.
|
28524155 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These agents co-induce p53 and NF-κB-dependent gene expression in cell lines from breast and colon cancer and in primary chronic lymphatic leukemia (CLL) cells.
|
27838375 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LRF inhibits p53 expression in colon cancer cells via modulating DAP5 activity.
|
28849590 |
2017 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of PHLDB3 more efficiently inhibits the growth of mouse xenograft tumours derived from human colon cancer HCT116 cells that contain wild type p53 compared with p53-deficient HCT116 cells, and also sensitizes tumour cells to doxorubicin and 5-Fluorouracil.
|
28008906 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, targeting BNIP3L in wild-type p53 colon cancer cells is a novel anticancer strategy activating iron depletion signaling and the mitophagy-related cell death pathway.
|
26517689 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this purpose, enrichment analysis was performed considering microRNAs (miRNAs) that putatively target TP53 and altered during colon cancer.
|
27629291 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer Cells.
|
27428957 |
2016 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of miR-34a-5p in p53 wild-type colon cancer cell HCT116 significantly inhibited cell growth, migration, invasion and metastasis. miR-34a-5p induced cell apoptosis, cell cycle arrest at G1 phase and p53 transcription activity in HCT116 cells, but not in the HCT116 p53 knockout (p53(-/-)) cells. miR-34a-5p significantly suppressed the HCT116 growth in vivo, whereas it showed no effect on the HCT116 p53(-/-) xenograft, indicating that the growth-inhibiting effect by miR-34a-5p was dependent on p53.
|
25362853 |
2015 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of p53 mediated miRNAs, cyto- and chemokines after radiation and SN38 treatment in colon cancer remains elusive.
|
26556872 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As p53 is a critical tumor suppressor in colon cancer, we tested the possibility that PHF2 is an epigenetic regulator of p53.
|
25043306 |
2015 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
|
26086041 |
2015 |